Business Context and Reporting Period
This Form 8-K Current Report from Palisade Bio, Inc. (PALI) covers events occurring on June 10, 2026, and June 11, 2026. The filing details the results of the Company's 2026 Annual Meeting of Stockholders and the subsequent appointment of a new director.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance and capital structure rather than operational financial performance.
Material Changes and Corporate Actions
- Board Expansion: The Board of Directors expanded from five to six members with the appointment of Jordan Zwick, who was also named to the Audit Committee.
- Director Compensation: Mr. Zwick received an initial grant of restricted stock units valued at $566,000, vesting in three equal annual installments.
- Capital Structure Amendment: Stockholders approved an amendment to the Certificate of Incorporation, increasing authorized common shares from 300,000,000 to 450,000,000. The total authorized capital stock increased from 307,000,000 to 457,000,000 shares.
- Equity Plans Approved: Stockholders approved the Amended and Restated 2021 Equity Incentive Plan and the Amended and Restated 2021 Employee Stock Purchase Plan.
Outlook, Risks, and Management Commentary
The filing confirms the ratification of Baker Tilly US, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. Management noted that the Board will take the advisory vote results on executive compensation under advisement. No specific risks, contingencies, or unusual items were disclosed in this filing.
Investor Verification Checklist
- Verify the impact of the increased authorized share count (450 million) on potential future dilution.
- Review the full text of the Amended and Restated 2021 Equity Incentive Plan (Exhibit 10.2) to understand new grant limits and terms.
- Confirm the vesting schedule and performance conditions associated with the $566,000 RSU grant to the new director.
- Monitor the "Votes Against" and "Withheld" tallies for the executive compensation advisory vote (Proposal 6), which saw significant dissent (approx. 31.8 million votes against).